Cue Biopharma, Inc. (CUE)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $18.66
- As of
Kresmion compiles this page from CUE's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Cue Biopharma, Inc. (CUE): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-21.
See the full CUE dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for CUE on one page. Preview it with sample data, then open it live with a free account.
Preview the CUE dossierActive signals for CUE
- mediumEarnings below estimates
Q2-2026: Missed consensus by 709.1%, EPS $-13.81 vs $-1.7069 estimate
- medium13F: new position
CITADEL ADVISORS LLC new position in CUE
- medium13F: new position
RENAISSANCE TECHNOLOGIES LLC new position in CUE
- mediumEarnings above estimates
Q2-2025: Beat consensus by 36.4% - EPS $-2.7 vs $-4.242 estimate
- mediumEarnings above estimates
Q4-2024: Beat consensus by 17.5% - EPS $-3.9 vs $-4.7268 estimate
FREE, NO ACCOUNT
Every signal on CUE, as it fires
You are seeing 5 of 8 signals recorded on CUE since 2026-05-24.
The five above landed across 4 days. The other 3 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in CUE (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 22978P205 · 2026Q2 | $809K | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 22978P205 · 2026Q2 | $464K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, CUE
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
CUE against its peers
CUE's operating margin of -96.7% ranks in the 81st percentile of 7 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2025-12-31.
| Metric | CUE | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 27.5M USD | 6.4M USD | 75 | 9 |
| Operating margin | -96.7% | -326.6% | 81 | 7 |
| Net margin | -96.9% | -296.5% | 81 | 7 |
| Return on equity | -100.6% | -52.3% | 21 | 16 |
Peers (20): ANTX, AVXL, KRRO, ALXO, MOLN, MSLE, VYGR, ABOS, NKTX, CNTN, MENS, TARA, NBP, MDWD, CMPX, NERV, NRXP, ORGO, ADAG, ARMP. Left out: TLSA (period gap), RNA (no annual filing), VRXA (no annual filing), RTSN (no annual filing), OTLK (no annual filing). Fiscal periods ending between 2025-09-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (CUE: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow CUE on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to CUE for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.